Systemic Sclerosis-associated Interstitial Lung Disease Market is expected to show positive growth

Systemic sclerosis (SSc), also referred to as scleroderma, is a rare chronic, multisystem connective tissue disease characterized by microangiopathy, diffuse fibrosis, and vascular abnormalities in the skin, joints, and internal organs (especially the esophagus, lower gastrointestinal tract, lungs, heart, and kidneys).

SSc encompasses a spectrum of related disorders, most of which share a characteristic clinical feature of skin thickening due to an excess of collagen fibers. The classification of SSc can be done based on limited systemic sclerosis, generalized systemic sclerosis, and systemic sclerosis sine scleroderma (Cutolo et al., 2019)

DelveInsight’s ‘Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the SSc-ILD, historical and forecasted epidemiology as well as the SSc-ILD market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Systemic Sclerosis-associated Interstitial Lung Disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Systemic Sclerosis-associated Interstitial Lung Disease market size from 2018 to 2030. The Report also covers current SSc-ILD treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

The DelveInsight Systemic Sclerosis-associated Interstitial Lung Disease market report gives the thorough understanding of the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) by including details such as disease definition, causes, symptoms, pathophysiology, and diagnostic trends. It also provides overview of treatment and management of the disease in the US, EU5 and Japan.

This segment of the SSc-ILD report encloses the detailed analysis of the marketed and emerging drugs. It also helps to understand the product description, clinical development, clinical trial details, approvals and other regulatory milestones, and the latest news and press releases. At present, therapeutic approach of SSc-ILD focuses on immunosuppressant therapies.

Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are the most commonly prescribed by doctors to patients having SSc-ILD. Azathioprine (AZA) and rituximab (RTX) are some other therapies that are also used. Currently, nintedanib (Boehringer Ingelheim) is the only approved drug for SSc-ILD, while pirfenidone (Beijing Continent Pharmaceutical/ Genentech) is under active investigation as potential new therapy for SSc-ILD.

The SSc-ILD market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Systemic Sclerosis-associated Interstitial Lung Disease market trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers. This segment gives a thorough detail of marketed therapies and emerging therapies by evaluating their impact based on annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) in the 7MM was found to be USD 214.16 million in 2017. This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of Systemic Sclerosis-associated Interstitial Lung Disease market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

For More Details of the key players- Systemic Sclerosis-associated Interstitial Lung Disease Market Companies

Latest Pharmaceuticals Market Research Reports 2022 by DelveInsight